Reading BMRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMRA free→Reading BMRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMRA free→QuarterlyIQ Insights · BMRA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On May 29, 2026 (the “Effective Date”), Biomerica, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the persons listed on Exhibit A thereto (the “Buyers”), whereby the Company agreed to sell to the Buyers 78,750 shares owned by the Company (the “Shares”) of Diagnosis S.A., a medical products producer and distributor headquartered in Białystok, Poland (“Diagnosis”), which represents approximate…
by reference. Forward-Looking Statements. This Form 8-K includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Form 8-K other than statements of historical fact sh…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective October 7, 2025, the Board of Directors (the “Board”) of Biomerica, Inc. (the “Company”) elected to increase the size of the Board from five directors to six directors and appointed Mr. Gary Huff to serve as an independent member of the Board, effective immediately. The new member of the Board was appointed to fill the vacancy on the Boar…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective June 4, 2025, Ms. Cathy Coste stepped down as a member of the Board of Directors (the “Board”) of Biomerica, Inc. (the “Company”). Ms. Coste’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. On the same date, the Board appointed Mr. Eric Chin to…
Material Modification to Rights of Security Holders The information contained in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.